NTHI
Neonc Technologies Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.03
+5.01%Aug 21, 2026, 00:00 UTC
NeonC Technologies Holdings, Inc. appointed Nasim Shomali as a member of its Board of Directors, effective July 1, 2026, and as a member of the Audit Committee, effective August 18, 2026.
Aug 18, 2026, 14:18 UTC
NeOnc Technologies Holdings CEO Amir Heshmatpour purchased 12,000 shares on August 14 and 3,000 shares on August 17, 2026, on the open market.
Source:Aug 12, 2026, 12:00 UTC
NeOnc Technologies reported positive topline Phase 2a results for its intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, meeting the primary endpoint of six-month progression-free survival.
Jun 23, 2026, 13:00 UTC
NeOnc Technologies received Investigational New Drug (IND) approval from the Department of Health – Abu Dhabi for its lead candidate NEO100, covering multiple clinical trial protocols.
Source:Jun 16, 2026, 17:49 UTC
The Department of Health - Abu Dhabi granted Investigational New Drug (IND) authorization for NeOnc Technologies Holdings' NEO212, an oral perillyl alcohol-temozolomide conjugate for aggressive brain tumors.
Jun 12, 2026, 00:00 UTC
NeonC Technologies Holdings, Inc. signed a private placement agreement to sell up to 6,000 shares of Series A Convertible Preferred Stock for up to $5,000,000.